Diplomat Pharmacy (DPLO) Tops Q4 EPS by 1c

Diplomat Pharmacy (NYSE: DPLO) reported Q4 EPS of $0.21, $0.01 better than the analyst estimate of $0.20. Revenue for the quarter came in at $987 million versus the consensus estimate of $969.7 million.

GUIDANCE:

Diplomat Pharmacy sees FY2016 EPS of $0.84-$0.89, versus the consensus of $1.00. Diplomat Pharmacy sees FY2016 revenue of $4.3-4.6 billion, versus the consensus of $4.45 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)